BioStock: Lipum on the CRO collaboration for phase I

The biopharmaceutical company Lipum recently reached a significant milestone when entering an agreement with QPS Netherlands for the execution of the first clinical study with the drug candidate SOL-116 against chronic inflammatory diseases. The preparatory work for the phase I study is proceeding according to plan and Lipum is now looking forward to starting the clinical study, according to Dr. Agneta Wennerholm in an interview with BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/lipum-on-the-cro-collaboration-for-phase-i/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se